SPP1 and prostate cancer: Doxorubicin plus osteopontin can inhibit the growth of prostate cancer cells through vDR receptor action in multiple pathways, including inhibition of proliferation, mediation of apoptosis, promotion of differentiation, and reduction of cell infiltration.